The brief

Analyst view

• UP421 (primary islet cells) achieved insulin production without immunosuppression in trial; published NEJM 14-month follow-up data.
• SC451 (iPSC-derived islets) planned IND filing 2026; uses same hypoimmune technology; Mayo partnership for development.
• HIP platform genetically modifies cells to hide from immune system, enabling transplants without lifelong immunosuppressive drugs.

Technical approach

As reported

Hypoimmune platform

HIP-modified cells

Genetic modifications hide islet cells from immune system, preventing allogeneic rejection and autoimmune attack.

Primary islet therapy

UP421 donor cells

UP421 uses human primary pancreatic islet cells from organ donors, engineered with HIP modifications to survive transplantation without immunosuppression.

Stem cell approach

SC451 iPSC-derived cells

SC451 is an O-negative, stem cell-derived version that promises unlimited cell supply, scalable manufacturing, and the same HIP immune evasion technology.